Evommune, Inc.
Close on Oct 19, 2026
- Market cap
- $190.43M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Dec 10, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | $-0.89 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | $-0.64 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | After market close | $0 | $-1.43 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Dec 11, 2025 | After market close | $10.00M | $-8.07 | – |
Press releases
Announcements Evommune filed with the SEC
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Regulation FD disclosure · EX-99.1 to Form 8-K
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Regulation FD disclosure · EX-99.1 to Form 8-K
Evommune Corporate Presentation September 2026 © Evommune, Inc.
Regulation FD disclosure · EX-99.1 to Form 8-K
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Regulation FD disclosure · EX-99.1 to Form 8-K
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 2026 © Evommune, Inc. Corporate Presentation
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Role of MRGPRX2 in Migraine April 13, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
March 2026 © Evommune, Inc. Corporate Presentation
Results of operations · EX-99.2 to Form 8-K
Evommune Announces $125 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Regulation FD disclosure · EX-99.1 to Form 8-K
EVO301 Top-Line Results from Phase 2a Trial in Moderate-to-Severe Atopic Dermatitis February 10, 2026 © Evommune, Inc.
Regulation FD disclosure · EX-99.2 to Form 8-K
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K